A detailed history of Signaturefd, LLC transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 1,171 shares of RCKT stock, worth $11,955. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,171
Previous 856 36.8%
Holding current value
$11,955
Previous $18,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$17.6 - $25.88 $5,544 - $8,152
315 Added 36.8%
1,171 $21,000
Q2 2024

Jul 29, 2024

BUY
$20.66 - $26.72 $413 - $534
20 Added 2.39%
856 $18,000
Q1 2024

May 03, 2024

BUY
$26.16 - $30.74 $209 - $245
8 Added 0.97%
836 $22,000
Q4 2023

Jan 31, 2024

SELL
$16.78 - $31.94 $1,141 - $2,171
-68 Reduced 7.59%
828 $24,000
Q3 2023

Nov 03, 2023

BUY
$15.07 - $24.05 $5,982 - $9,547
397 Added 79.56%
896 $18,000
Q2 2023

Aug 01, 2023

BUY
$16.59 - $23.6 $1,360 - $1,935
82 Added 19.66%
499 $9,000
Q2 2022

Aug 10, 2022

BUY
$7.96 - $16.64 $1,217 - $2,545
153 Added 57.95%
417 $6,000
Q1 2022

May 02, 2022

BUY
$13.16 - $23.68 $3,184 - $5,730
242 Added 1100.0%
264 $4,000
Q4 2021

Jan 25, 2022

BUY
$21.52 - $36.02 $86 - $144
4 Added 22.22%
22 $0
Q3 2021

Oct 28, 2021

SELL
$27.42 - $48.97 $356 - $636
-13 Reduced 41.94%
18 $1,000
Q2 2021

Jul 26, 2021

BUY
$39.41 - $47.25 $1,221 - $1,464
31 New
31 $1,000
Q1 2021

Apr 30, 2021

SELL
$43.34 - $65.91 $1,386 - $2,109
-32 Closed
0 $0
Q4 2020

Feb 11, 2021

BUY
$23.3 - $59.57 $745 - $1,906
32 New
32 $2,000
Q2 2020

Jul 30, 2020

SELL
$13.32 - $22.61 $745 - $1,266
-56 Closed
0 $0
Q4 2019

Feb 05, 2020

BUY
$11.07 - $24.23 $619 - $1,356
56 New
56 $1,000

Others Institutions Holding RCKT

About ROCKET PHARMACEUTICALS, INC.


  • Ticker RCKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 75,683,696
  • Market Cap $773M
  • Description
  • Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...
More about RCKT
Track This Portfolio

Track Signaturefd, LLC Portfolio

Follow Signaturefd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.